Evidence map›Paper›PMID 24951495›Full record

Trial reportNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2014

Early quit days among methadone-maintained smokers in a smoking cessation trial.

Marcel A de Dios, Bradley J Anderson, Celeste M Caviness, Michael D Stein

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Nicotine receptor partial agonists for smoking cessation.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Nicotine replacement therapy versus control for smoking cessation.The Cochrane database of systematic reviews · 2018
    Pooled it
  3. Nicotine receptor partial agonists for smoking cessation.The Cochrane database of systematic reviews · 2016
    Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Are Pharmacotherapies Ineffective in Opioid-Dependent Smokers? Reflections on the Scientific Literature and Future Directions.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Marcel A de DiosDepartment of Health Disparities Research, University of Texas MD Anderson Cancer Center, Houston, TX; made@mdanderson.org.
Bradley J AndersonButler Hospital, Providence, RI;
Celeste M CavinessButler Hospital, Providence, RI;
Michael D SteinButler Hospital, Providence, RI; Department of Medicine, Warren Alpert Medical School, Brown University, Providence, RI; Department of Health Services, Policy, and Practice, Warren Alpert Medical School, Brown University, Providence, RI.

Funding

Varenicline versus Nicotine Replacement for Methadone-Maintained SmokersR01CA129226 · NCI · BUTLER HOSPITAL (PROVIDENCE, RI) · PI STEIN, MICHAEL D · 2008 to 2012
$2.6M
MIDCAREER INVESTIGATOR AWARD IN SUBSTANCE ABUSE RESEARCHK24DA000512 · NIDA · RHODE ISLAND HOSPITAL (PROVIDENCE, RI) · PI STEIN, MICHAEL D · 2001 to 2010
$982k
Project Impact: A Culturally-Tailored Adherence Intervention for Latino SmokersK01CA160670 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DE DIOS, MARCEL ALEJANDRO · 2012 to 2016
$701k
NCI NIH HHS K01CA160670NCI NIH HHS R01CA129226NIDA NIH HHS K24 DA00512
6 · The paper itself

Abstract

introductionMethadone maintenance treatment (MMT) patients have an exceedingly high prevalence of tobacco use, and interventions that have been specifically developed for this vulnerable subpopulation have struggled to attain even modest rates of cessation. A significant barrier has been an inability to initiate a quit attempt early in the treatment process and adherence to treatment.

methodsThis study examined the extent to which self-efficacy, medication adherence, and other demographic and smoking variables predicted an early quit day in a sample of MMT smokers (n = 315) enrolled in a smoking cessation pharmacotherapy trial. Using logistic regression, we estimated the association of having an early quit day-24hr without smoking during the first month of treatment.

resultsOnly 35.2% of participants reported a successful early quit day. The likelihood of an early quit day increased significantly (odds ratio [OR] = 1.39, 95% CI = 1.04-1.86, p < .05) with education level and if a quit attempt was made in the past year (OR = 2.27, 95% CI = 1.33-3.87, p < .01). Compared to the placebo arm, those randomized to either nicotine replacement therapy (OR = 3.25, 95% CI = 1.30-8.10, p < .01) or varenicline (OR = 3.16, 95% CI = 1.26-7.92) were significantly more likely to have an early quit day. The likelihood of an early quit day was also positively associated with adherence to the medication protocol (OR = 2.05, 95% CI = 1.52-2.76).

conclusionsDifficulty in achieving an early quit attempt may help explain the very low cessation rates found in studies of MMT smokers.

Indexed as

AdultBenzazepinesFemaleHumansMaleMedication AdherenceMethadoneMiddle AgedOpiate Substitution TreatmentQuinoxalinesSelf EfficacySmokingSmoking CessationTime FactorsVareniclineBenzazepinesMethadoneQuinoxalinesVarenicline

Identifiers

PMID24951495
PMCPMC4271088

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.